MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
2023: Top 20 Genomics Companies in the World
Natera, Inc. (NASDAQ:NTRA), formerly Gene Security Network Inc.
Organization & Developments: Natera
Parents
Natera, Inc. (NASDAQ:NTRA), formerly Gene Security Network Inc.
Children
*By combining data from the human genome project with advanced bioinformatics, GSN delivers single cell diagnostics with over ten times greater accuracy than conventional technology.
*Natera, Inc. provides preconception and prenatal genetic testing services.
*The test looks for severe fetal genetic abnormalities by testing fetal DNA found in maternal blood
2012: Gene Security Network Announces Completion of $20 Million Financing Round, Change of Company Name to Natera (2012)
2018: Natera: A Quick Look At A Growing Testing Concern_seekingalpha.com
2019: Genetic Testing Companies Take DNA Tests To A Whole New Level
2022: Natera Awarded Contract to Provide Cancer Testing Services to VA
2022: Natera, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Natera: Management Stuck In A Growth At All Cost Mentality_ seekingalpha.com
2022: Natera's Worrisome Cash Burn_ seekingalpha.com
2022: Natera’s Prospera is a transplant rejection assessment blood test that can evaluate the rejection of a transplanted kidney.
2022: Natera’s Signatera is a molecular residual disease assay (MRD) that identifies cancer relapse earlier than standard-of-care tools.
2023: Natera: Cash Burn Remains A Concern
2023: Natera: Squeezing The Last Drop From NIPT Growth Engine_ seekingalpha.com
2024: Decoding Natera Inc (NTRA): A Strategic SWOT Insight
2024: Invitae Fights Natera's Bid to Amplify $19 Million Patent Win
2024: Invitae sells reproductive health assets amid liquidity concerns
2024: Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds
2024: Natera: Capitalizing On The Positive Momentum Of Personalized Medicin
2024: Natera: Focus On Signatera And H1 2024 Results_ seekingalpha.com
2024: Natera: Poised For A Great Future But I'd Wait For A Pullback
2025: Natera: Strong Growth Trajectory Despite Stretched Valuation Metrics_
Jumps
*Key People: Natera
Finance & Acquisitions: Natera